NPS PHARMACEUTICALS INC 4

Accession 0001104659-15-013588

CIK 0000890465operating

View on SEC.gov Company Profile

Filed

Feb 23, 7:00 PM ET

Accepted

Feb 24, 9:17 PM ET

Size

36.5 KB

Accession

0001104659-15-013588

Insider Transaction Report

Form 4

Period: 2015-02-21

NPS PHARMACEUTICALS INCNPSP

Nader Francois

DirectorPresident, CEO and Director

Transactions

Disposition to Issuer
Stock Options
2015-02-21−133,125→ 0 total
Exercise: $8.25Exp: 2021-02-17→ Common Stock (133,125 underlying)
Disposition to Issuer
Stock Options
2015-02-21−82,826→ 0 total
Exercise: $5.71Exp: 2019-01-20→ Common Stock (82,826 underlying)
Disposition to Issuer
Restricted Stock Units
2015-02-21−24,302→ 0 total
→ Common Stock (24,302 underlying)
Disposition to Issuer
Stock Options
2015-02-21−106,643→ 0 total
Exercise: $38.27Exp: 2024-02-12→ Common Stock (106,643 underlying)
Disposition to Issuer
Stock Options
2015-02-21−154,284→ 0 total
Exercise: $3.34Exp: 2020-02-19→ Common Stock (154,284 underlying)
Disposition to Issuer
Performance Units
2015-02-21−27,926→ 0 total
→ Common Stock (27,926 underlying)
Disposition to Issuer
Stock Options
2015-02-21−196,018→ 0 total
Exercise: $8.23Exp: 2023-02-13→ Common Stock (196,018 underlying)
Disposition to Issuer
Stock Options
2015-02-21−67,636→ 0 total
Exercise: $3.25Exp: 2020-02-12→ Common Stock (67,636 underlying)
Disposition to Issuer
Stock Options
2015-02-21−109,602→ 0 total
Exercise: $5.71Exp: 2019-01-20→ Common Stock (109,602 underlying)
Disposition to Issuer
Restricted Stock Units
2015-02-21−80,912→ 0 total
→ Common Stock (80,912 underlying)
Disposition to Issuer
Stock Options
2015-02-21−104,438→ 0 total
Exercise: $8.21Exp: 2022-02-07→ Common Stock (104,438 underlying)
Disposition to Issuer
Restricted Stock Units
2015-02-21−19,598→ 0 total
→ Common Stock (19,598 underlying)
Disposition to Issuer
Performance Units
2015-02-21−115,432→ 0 total
→ Common Stock (115,432 underlying)
Disposition from Tender
Common Stock
2015-02-21$46.00/sh−276,955$12,739,930→ 0 total

Footnotes (18)

[F1]In connection with the merger of Knight Newco 2, Inc. with and into NPS Pharmaceuticals, Inc. (the "Issuer") on February 21, 2015, each outstanding stock option, whether vested or unvested, was cancelled in exchange for a single lump sum cash payment in an amount equal to the product of (1) the number of shares of the Issuer's common stock subject to such stock option and (2) the execess, if any, of $46.00 over the exercise price per share of such stock option.
[F10]On February 13, 2013, the Performance Units were granted subject to vesting based on the Issuer's satisfaction of certain performance criteria during the performance periods.
[F11]On February 12, 2014, the stock options were granted with one fourth vesting on the first anniversary of date of grant and 6.25% vesting every three months thereafter.
[F12]On February 13, 2013, the stock options were granted with one fourth vesting on the first anniversary of date of grant and 6.25% vesting every three months thereafter.
[F13]On February 7, 2012, the stock options were granted with one fourth vesting on the first anniversary of date of grant and 6.25% vesting every three months thereafter.
[F14]On February 17, 2011, the stock options were granted with one fourth vesting on the first anniversary of date of grant and 6.25% vesting every three months thereafter.
[F15]On February 19, 2010, the stock options were granted with one fourth vesting on the first anniversary of date of grant and 6.25% vesting every three months thereafter.
[F16]On February 12, 2010, the stock options were granted with one fourth vesting on the first anniversary of date of grant and 6.25% vesting every three months thereafter.
[F17]On January 20, 2009, the stock options were granted with one fourth vesting on the first anniversary of date of grant and 6.25% vesting every three months thereafter.
[F18]On January 20, 2009, the stock options were granted with one half vesting on the second anniversary of date of grant and one half vesting on the third anniversary of date of grant, with the actual number of options vesting on such dates determined based on specified performance criteria.
[F2]Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock.
[F3]On February 12, 2015, the Restricted Stock Units were granted with (i) one third vesting on the first anniversary of date of grant, (ii) one third on the second anniversary of date of grant and (iii) one third on the third anniversary of date of grant.
[F4]In connection with the merger of Knight Newco 2, Inc. with and into the Issuer on February 21, 2015, each outstanding Restricted Stock Unit was cancelled in exchange for a lump sum cash payment in an amount equal to the product of (1) $46.00 and (2) the number of shares of common stock subject to such Restricted Stock Unit.
[F5]On February 12, 2014, the Restricted Stock Units were granted with (i) one third vesting on the first anniversary of date of grant, (ii) one third on the second anniverary of date of grant and (iii) one third on the third anniverary of date of grant.
[F6]On February 13, 2013, the Restricted Stock Units were granted with (i) one third vesting on the first anniversary of date of grant, (ii) one third on the second anniverary of date of grant and (iii) one third on the third anniverary of date of grant.
[F7]Each performance unit represents a contingent right to receive one share of the Issuer's common stock.
[F8]On February 12, 2014, the Performance Units were granted subject to vesting based on the satisfaction of certain performance criteria by the Issuer and/or the reporting person during the performance periods.
[F9]In connection with the merger of Knight Newco 2, Inc. with and into the Issuer on February 21, 2015, each outstanding Performance Unit was cancelled in exchange for a lump sum cash payment in an amount equal to the product of (1) $46.00 and (2) the number of shares of common stock subject to such Performance Unit, which number was determined as if the applicable performance objectives had been achieved at the target performance level.

Documents

1 file

4
a4.xmlPrimary
4

Issuer

NPS PHARMACEUTICALS INC

CIK 0000890465

→

Entity typeoperating

IncorporatedDE

Related Parties

filerCIK 0000890465

Filing Metadata

Form type: 4
Filed: Feb 23, 7:00 PM ET
Accepted: Feb 24, 9:17 PM ET
Size: 36.5 KB

View on SEC.gov